After H.C. Wainwright and Cantor Fitzgerald gave Abeona Therapeutics (NASDAQ: ABEO) a Buy rating last month, the company received another Buy, this time from Maxim Group. Analyst Jason McCarthy maintained a Buy rating on Abeona Therapeutics today and set a price target of $35. The company’s shares opened today at $10.32, close to its 52-week low of $9.66.
McCarthy wrote:
“We note that today Sarepta Therapeutics (SRPT – NR) and Lysogene SA (EPA: LYS – NR) announced a license agreement for Lysogene’s LYS-SAF302 gene therapy for Sanfilippo Syndrome, or mucopolysaccharidosis type IIIA (MPS IIIA)…same indication as for Abeona.”
According to TipRanks.com, McCarthy is a 5-star analyst with an average return of 11.7% and a 47.6% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as SELLAS Life Sciences Group Inc, ContraVir Pharmaceuticals Inc, and Sonoma Pharmaceuticals Inc.
Abeona Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $29.50, representing a 185.9% upside. In a report issued on October 1, Cantor Fitzgerald also maintained a Buy rating on the stock with a $36 price target.
.
See today’s analyst top recommended stocks >>
The company has a one-year high of $22 and a one-year low of $9.66. Currently, Abeona Therapeutics has an average volume of 534.9K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Abeona Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development of gene therapy for severe and life threatening rare diseases. It programs include EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA) and ABO-101 (AAV NAGLU), an AAV based gene therapy for Sanfilippo syndrome type B (MPS IIIB). The company was founded in 1974 and is headquartered in Dallas, TX.
